Your browser doesn't support javascript.
loading
Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.
Hartleben, Goetz; Schorpp, Kenji; Kwon, Yun; Betz, Barbara; Tsokanos, Foivos-Filippos; Dantes, Zahra; Schäfer, Arlett; Rothenaigner, Ina; Monroy Kuhn, José Manuel; Morigny, Pauline; Mehr, Lisa; Lin, Sean; Seitz, Susanne; Tokarz, Janina; Artati, Anna; Adamsky, Jerzy; Plettenburg, Oliver; Lutter, Dominik; Irmler, Martin; Beckers, Johannes; Reichert, Maximilian; Hadian, Kamyar; Zeigerer, Anja; Herzig, Stephan; Berriel Diaz, Mauricio.
Afiliación
  • Hartleben G; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Schorpp K; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Kwon Y; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Betz B; Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Tsokanos FF; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Dantes Z; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Schäfer A; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Rothenaigner I; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Monroy Kuhn JM; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Morigny P; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Mehr L; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Lin S; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Seitz S; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Tokarz J; Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Artati A; Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Adamsky J; Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Plettenburg O; Institute for Diabetes and Obesity, Neuherberg, Germany.
  • Lutter D; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Irmler M; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Beckers J; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Reichert M; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Hadian K; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Zeigerer A; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Herzig S; Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Berriel Diaz M; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
EMBO Mol Med ; 13(4): e12461, 2021 04 09.
Article en En | MEDLINE | ID: mdl-33665961

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Alemania